XERMELO is a tryptophan hydroxylase inhibitor indicated for the treatment of carcinoid syndrome diarrhea (CSD) in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.

Dedicated care, every step of the way

SupportSource logo

TerSera SupportSource partners with CoverMyMeds to provide a comprehensive support program for patients.

TerSera SupportSource is committed to helping appropriate patients gain access to XERMELO. Several options are available for eligible patients based on personal needs.

How TerSera SupportSource can help

Reimbursement hub powered by CoverMyMeds

To help patients start and stay on therapy, TerSera Therapuetics LLC is leveraging CoverMyMeds’ trusted technology and solutions to provide access to patient support services, including electronic prior authorizations, benefits investigations, appeals, and other reimbursement information. CoverMyMeds enables access to patient support services for TerSera SupportSource while providing consistent visibility into the patient journey.

Patient Assistance Program

The challenges of dealing with a treatment can be made more difficult when a person lacks any form of insurance. We are committed to helping eligible patients access the medication they need through our Patient Assistance Program.

Some features include:

  • Patients who establish financial need can receive free product through the Patient Assistance Program
  • If a patient qualifies, they may get free TerSera medicine for up to 1 year
  • TerSera will send an application for renewal once the patient’s enrollment ends

Download the enrollment form to get your patients started with TerSera SupportSource

Download form

TerSera NurseSupport offers one-on-one support for XERMELO patients

Let your XERMELO patients know they can get support from one of our dedicated nurse educators, who can answer questions about XERMELO.

When your patients sign up with TerSera NurseSupport, they will get a dedicated expert who can offer one-on-one help and be available to answer their questions. Our specialized nurses can:

  • Help patients stay on track with treatment by helping make XERMELO part of their routine
  • Easily identify Carcinoid Syndrome Diarrhea-friendly foods (they’ll receive a FREE nutrition guide, too)
  • Help them learn about the role of hormones, including serotonin, in NETs
  • Set up convenient text reminders to take their medication three times a day (optional)

Note: TerSera NurseSupport is an informational service that is available without charge to anyone seeking support for managing with Neuroendocrine Tumors (NETs) and/or Carcinoid Syndrome Diarrhea (CSD), or with TerSera products. No purchase or prescription is necessary. TerSera NurseSupport consists of registered nurses who are employed or contracted by TerSera Therapeutics, LLC, a manufacturer of pharmaceutical products, for the limited purpose of providing generalized information about navigating with NET and/or CSD and product information and support regarding TerSera products. Importantly, TerSera NurseSupport nurses are not personal clinicians and do not provide any medical or clinical advice or patient-specific information. If patients have questions about their medical treatment, need medical care, or are experiencing a medical concern or emergency, they should call their physician or treating clinician, or, in the case of an emergency, dial 911 immediately.

Patients with commercial insurance may be eligible* for a co-pay as low as $0

TerSera SupportSource can provide assistance to eligible, commercially insured patients to help reduce out-of-pocket costs for a XERMELO prescription. Eligible patients may pay as little as $0 co-pay up to $10,000 per year. The specialty pharmacy will process the co-pay.

For patients with Medicare, Medicaid, or no insurance, TerSera SupportSource will help identify an appropriate patient assistance program if available for qualifying patients.

The program may be able to help your patients understand their existing insurance coverage.

Our specialty pharmacies can help at any turn

TerSera SupportSource has partnered with Diplomat and Biologics specialty pharmacies to guide patients through getting and starting XERMELO. Diplomat and Biologics are patient-focused specialty pharmacies and are committed to being a part of the care team.

Diplomat and Biologics will coordinate with patients, physicians, nurses, and office staff to ensure everyone has the most up-to-date information.

TerSera SupportSource will connect with the physician’s office if additional forms or information is required.

Biologics specialty pharmacies

After you and your patient sign the enrollment form, fax the form to one of the following specialty pharmacies:

Biologics
Fax: 1-800-823-4506
Phone: 1-800-850-4306

TerSera SupportSource

TerSera SupportSource will verify insurance coverage, identify any available financial assistance, and arrange prescription delivery with your patients.

Access the forms you need to get started

Forms and downloads

What is CSD?

For patients with CSD, SSA treatment alone may not be enough.

Learn about CSD

Study results

See study results of XERMELO + SSA treatment versus SSA treatment alone.

See study results

Request a representative

Have questions? Contact a XERMELO representative who can answer your questions and provide ongoing support.

Request a rep

*Eligibility Criteria

Eligibility cannot be determined until all of the information submission requirements have been met by the healthcare professional, patient, and/or caregiver. Please refer to the Enrollment Form for details.

Patient financial information and insurance status are required to determine whether a patient qualifies for assistance, and which TerSera SupportSource financial support offering is appropriate for the patients.

Patients not eligible for financial assistance through TerSera SupportSource may be able to obtain financial support through other programs. Our representatives will assist you in finding other options.

Customers are not eligible if prescriptions are paid for by any state or other federally funded programs, including, but not limited to, Medicare or Medicaid, Medigap, VA or DOD or TRICARE, or where prohibited by law. TerSera Therapeutics reserves the right to rescind, revoke, or amend this offer at any time.

Important Safety Information and Indication

  • Contraindications: XERMELO is contraindicated in patients with a history of a hypersensitivity reaction to telotristat. Reactions have included angioedema, rash and pruritis.
  • Warnings and Precautions: XERMELO may cause constipation, which can be serious. Serious complications of constipation have been reported during clinical trials and post marketing with individual reports of intestinal perforation, obstruction, and fecaloma. Monitor for signs and symptoms of constipation and/or severe, persistent, or worsening abdominal pain in patients taking XERMELO. Discontinue XERMELO if severe constipation or severe, persistent, or worsening abdominal pain develops.
  • Contraindications: XERMELO is contraindicated in patients with a history of a hypersensitivity reaction to telotristat. Reactions have included angioedema, rash and pruritis.
  • Warnings and Precautions: XERMELO may cause constipation, which can be serious. Serious complications of constipation have been reported during clinical trials and post marketing with individual reports of intestinal perforation, obstruction, and fecaloma. Monitor for signs and symptoms of constipation and/or severe, persistent, or worsening abdominal pain in patients taking XERMELO. Discontinue XERMELO if severe constipation or severe, persistent, or worsening abdominal pain develops.
  • Adverse Reactions: In a clinical trial of patients with carcinoid syndrome diarrhea and 4-12 bowel movements per day, the most common adverse reactions (≥5%) include nausea, headache, increased gamma-glutamyl transferase, depression, flatulence, decreased appetite, peripheral edema, and pyrexia. In a second clinical trial of patients with carcinoid syndrome diarrhea and less than 4 bowel movements per day, additional adverse reactions of abdominal pain and constipation were reported in ≥5% of patients.
  • Drug Interactions: If necessary, consider increasing the dose of concomitant CYP3A4 and CYP2B6 substrates, as XERMELO may decrease their systemic exposure. If combination treatment with XERMELO and short-acting octreotide is needed, administer short-acting octreotide at least 30 minutes after administering XERMELO.
  • Use in Special Populations: XERMELO is not recommended in patients with moderate and severe hepatic impairment.

Indication

XERMELO is a tryptophan hydroxylase inhibitor indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.

Please see Full Prescribing Information.

To report suspected adverse reactions, contact the FDA at 1-800-FDA-1088 or www.FDA.gov/medwatch. You may also contact TerSera Therapeutics at 1-844-334-4035 or medicalinformation@tersera.com.

 

Important Safety Information and Indication

  • Contraindications: XERMELO is contraindicated in patients with a history of a hypersensitivity reaction to telotristat. Reactions have included angioedema, rash and pruritis.
  • Warnings and Precautions: XERMELO may cause constipation, which can be serious. Serious complications of constipation have been reported during clinical trials and post marketing with individual reports of intestinal perforation, obstruction, and fecaloma. Monitor for signs and symptoms of constipation and/or severe, persistent, or worsening abdominal pain in patients taking XERMELO. Discontinue XERMELO if severe constipation or severe, persistent, or worsening abdominal pain develops.
  • Contraindications: XERMELO is contraindicated in patients with a history of a hypersensitivity reaction to telotristat. Reactions have included angioedema, rash and pruritis.
  • Warnings and Precautions: XERMELO may cause constipation, which can be serious. Serious complications of constipation have been reported during clinical trials and post marketing with individual reports of intestinal perforation, obstruction, and fecaloma. Monitor for signs and symptoms of constipation and/or severe, persistent, or worsening abdominal pain in patients taking XERMELO. Discontinue XERMELO if severe constipation or severe, persistent, or worsening abdominal pain develops.
  • Adverse Reactions: In a clinical trial of patients with carcinoid syndrome diarrhea and 4-12 bowel movements per day, the most common adverse reactions (≥5%) include nausea, headache, increased gamma-glutamyl transferase, depression, flatulence, decreased appetite, peripheral edema, and pyrexia. In a second clinical trial of patients with carcinoid syndrome diarrhea and less than 4 bowel movements per day, additional adverse reactions of abdominal pain and constipation were reported in ≥5% of patients.
  • Drug Interactions: If necessary, consider increasing the dose of concomitant CYP3A4 and CYP2B6 substrates, as XERMELO may decrease their systemic exposure. If combination treatment with XERMELO and short-acting octreotide is needed, administer short-acting octreotide at least 30 minutes after administering XERMELO.
  • Use in Special Populations: XERMELO is not recommended in patients with moderate and severe hepatic impairment.

Indication

XERMELO is a tryptophan hydroxylase inhibitor indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.

Please see Full Prescribing Information.

To report suspected adverse reactions, contact the FDA at 1-800-FDA-1088 or www.FDA.gov/medwatch. You may also contact TerSera Therapeutics at 1-844-334-4035 or medicalinformation@tersera.com.

Attention

If you click “Continue” below, you will leave the current site and be taken to a site maintained by a third party who is solely responsible for its content. TerSera provides this link as a service to website visitors. TerSera is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit.

Continue

NPI LOOKUP

To find your NPI number, please fill out the information below.

Fields marked with an asterisk (*) are required.

Enter your first name.
Enter your last name.
Select your state.

Search results

Select the entry with your name and address information.  

Name NPI number State ZIP Code  

No results found

Refine your search and try again.